RecruitingNCT05915208

Histiocytic Disorder Follow-up Study


Sponsor

University of Alabama at Birmingham

Enrollment

6,000 participants

Start Date

Sep 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders


Eligibility

Min Age: 0 YearsMax Age: 89 Years

Plain Language Summary

Simplified for easier understanding

This is a long-term follow-up registry study for patients diagnosed with histiocytic disorders — a group of rare diseases where certain immune cells (histiocytes) grow abnormally. The registry tracks health outcomes over time. **You may be eligible if...** - You have been diagnosed with a histiocytic disorder at any age, including: - Langerhans cell histiocytosis (LCH) - Erdheim-Chester disease - Rosai-Dorfman disease - Xanthogranuloma - Malignant histiocytosis **You may NOT be eligible if...** - You do not have a confirmed diagnosis of a histiocytic disorder - You are unwilling to participate in long-term follow-up Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

University of Alabama at Birmingham

Birmingham, Alabama, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05915208


Related Trials